Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The investigators investigate the change in the maxLCBI (4 mm) value calculated by NIRS‐IVUS at the time of PCI and at the treatment evaluation after 9 months compared with the group of Alirocumab(Alirocumab75mg/2week+losuvastatin10mg/daily) and standard treatment (losuvastatin10mg/daily alone). And also the investigators evaluate LCBI(lesion), Angle of a lipid core, EEM CSA, Lumen CSA, Minimum lumen diameter, Plaque burden, Lesion length by NIRS‐IVUS.
Epistemonikos ID: 0873e72e325a524353d4ce45c24082170a298411
First added on: May 21, 2024